Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases [Yahoo! Finance]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Yahoo! Finance
XmAb942 is a high-potency, extended half-life, investigational anti-TL1A antibody to be developed for patients with inflammatory bowel diseases, such as ulcerative colitis (UC) and Crohn's disease (CD). The first generation of anti-TL1A antibodies, designed to block the interaction between the DR3 receptor and its ligand TL1A, have reduced disease activity in patients with UC and CD in multiple clinical studies. Xencor anticipates dosing the first subject in a first-in-human study of XmAb942 in healthy volunteers during the fourth quarter of 2024 and expects to present initial data from the single-ascending dose portion of the study in the first half of 2025. "We are aiming for XmAb942 to be the potential best-in-class next-generation anti-TL1A antibody, providing leading potency and less frequent dosing relative to the first generation TL1A-targeted antibodies, which have validated TL1A as an important inflammatory axis," said John Desjarlais, Ph.D., executive vice president and c
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Xencor: Plamotamab NHL Data Leads To RA Program Advancement [Seeking Alpha]Seeking Alpha
- Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.MarketBeat
- Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
XNCR
Earnings
- 11/6/24 - Beat
XNCR
Sec Filings
- 11/21/24 - Form 144
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- XNCR's page on the SEC website